Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genfit
Biotech
Genfit ends liver failure program over phase 2 safety signal
Genfit has stopped development of VS-01 in acute-on-chronic liver failure after a patient suffered a serious adverse event in a phase 2 trial.
Nick Paul Taylor
Sep 22, 2025 5:14am
Genfit moves to jump-start enrollment in liver failure trial
Sep 20, 2024 9:47am
Ipsen posts mixed liver disease data on Intercept, CymaBay rival
Nov 14, 2023 5:55am
Ipsen, Genfit report phase 3 rare liver disease success
Jun 30, 2023 6:15am
Genfit licenses liver failure drug from Seal Rock in $107M deal
Jun 1, 2023 8:25am
Genfit revs up liver failure strategy with $41M biotech buyout
Sep 19, 2022 7:00am
